Histamine dihydrochloride and interleukin-2 in acute myeloid leukemia - Background and results

被引：3
|
作者：
Brune M. [1 ]
Romero A.I. [1 ]
Hellstrand K. [1 ]
机构：
[1] Department of Infectious Diseases, Sahlgrenska Academy, Göteborg University, Göteborg 413 46
来源：
Inflammation Research | 2009年 / 58卷 / Suppl 1期
关键词：
Natural Killer Cell; Acute Myeloid Leukemia; Acute Myeloid Leukemia Patient; Pediatric Acute Myeloid Leukemia; Acute Myeloid Leukemia Blast;
D O I：
10.1007/s00011-009-0642-1
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：S4 / S8
页数：4
相关论文
共 50 条
  • [21] Spotlight on Histamine Dihydrochloride in Acute Myeloid Leukaemia
    Yang, Lily P. H.
    Perry, Caroline M.
    [J]. DRUGS & AGING, 2011, 28 (04) : 325 - 329
  • [22] COST-EFFECTIVENESS ANALYSIS OF HISTAMINE DIHYDROCHLORIDE plus LOW DOSE INTERLEUKIN-2 VS STANDARD OF CARE FOR ACUTE MYELOID LEUKEMIA PATIENTS IN THEIR FIRST COMPLETE REMISSION: A UK PERSPECTIVE
    Magar, R. S.
    Purdy, C.
    Hayward, A.
    Einarson, T. R.
    Burnett, A. K.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A272 - A272
  • [23] Histamine dihydrochloride and interleukin-2 for relapse prevention in AML: Initial results of the Re: MISSION phase IV trial
    Martner, Anna
    Rydstrom, Anna
    Riise, Rebecca
    Aurelius, Johan
    Brune, Mats
    Hellstrand, Kristoffer
    Thoren, Fredrik Bergh
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [24] Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma
    Perz, Jolanta B.
    Ho, Anthony D.
    [J]. FUTURE ONCOLOGY, 2008, 4 (02) : 169 - 177
  • [25] ACUTE MYELOID-LEUKEMIA RELAPSING FOLLOWING INTERLEUKIN-2 TREATMENT EXPRESSES THE ALPHA-CHAIN OF THE INTERLEUKIN-2 RECEPTOR
    MACDONALD, D
    JIANG, YZ
    SWIRSKY, D
    VULLIAMY, T
    MORILLA, R
    BUNGEY, J
    BARRETT, AJ
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1991, 77 (01) : 43 - 49
  • [26] Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma
    Agarwala, SS
    Glaspy, J
    O'Day, SJ
    Mitchell, M
    Gutheil, J
    Whitman, E
    Gonzalez, R
    Hersh, E
    Feun, L
    Belt, R
    Meyskens, F
    Hellstrand, K
    Wood, D
    Kirkwood, JM
    Gehlsen, KR
    Naredi, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 125 - 133
  • [27] Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-α in patients with metastatic melanoma
    Lindnér, P
    Rizell, M
    Mattsson, J
    Hellstrand, K
    Naredi, P
    [J]. ANTICANCER RESEARCH, 2004, 24 (3B) : 1837 - 1842
  • [28] Interleukin-2 therapy for advanced chronic myeloid leukemia
    Goodman, M
    Spector, N
    Rodrigues, G
    Cassileth, PA
    [J]. LEUKEMIA, 1998, 12 (11) : 1682 - 1684
  • [29] Interleukin-2 therapy for advanced chronic myeloid leukemia
    M Goodman
    N Spector
    G Rodrigues
    PA Cassileth
    [J]. Leukemia, 1998, 12 : 1682 - 1684
  • [30] Interleukin-2 (IL-1) expression in untreated acute myeloid leukemia (AML).
    Powell, BL
    Gregory, BW
    Shelton, BJ
    Lyerly, ES
    Cottrell, DL
    Williams, MB
    Mizel, SB
    [J]. BLOOD, 1995, 86 (10) : 3088 - 3088
12345